Posterior Juxtascleral Depot Administration of Anecortave Acetate
Abstract Objective To develop a safe and effective transcleral delivery of anecortave acetate, a novel angiostatic cortisene, in therapeutic concentrations to the choroid and retina in the region of the macula in patients with age related macular degeneration. Methods In pre-clinical studies with ra...
Gespeichert in:
| Veröffentlicht in: | Survey of ophthalmology 2007, Vol.52 (1), p.S62-S69 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | S69 |
|---|---|
| container_issue | 1 |
| container_start_page | S62 |
| container_title | Survey of ophthalmology |
| container_volume | 52 |
| creator | Kaiser, Peter K., MD Goldberg, Morton F., MD Davis, Alberta A., PhD |
| description | Abstract Objective To develop a safe and effective transcleral delivery of anecortave acetate, a novel angiostatic cortisene, in therapeutic concentrations to the choroid and retina in the region of the macula in patients with age related macular degeneration. Methods In pre-clinical studies with rabbits and monkeys, several routes of delivery were studied including oral and other systemic routes as well as topical, subconjunctival, intravitreal injections and posterior juxtascleral administration. In addition, posterior juxtascleral depot administration using a specially designed blunt cannula was evaluated in humans. Results Oral and other systemic routes were not acceptable due to rapid systemic metabolism. Topical and subconjunctival administrations resulted in subtherapeutic concentrations in the macular region ( |
| doi_str_mv | 10.1016/j.survophthal.2006.10.015 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_68935373</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S0039625706002098</els_id><sourcerecordid>68935373</sourcerecordid><originalsourceid>FETCH-LOGICAL-c430t-9cbc3dd907b1e1bab827ae7d3a46b6df6eefd4172c3585506d791cdf6cd811433</originalsourceid><addsrcrecordid>eNqNkU1v1DAQhq0KRLeFv1CFC7dsx3FixxekaIG2qBJILWfLsSeql2y82M6K_nsc7UqgnjiN9M47X88Q8p7CmgLl19t1nMPB75_Skx7XFQDP-hpoc0ZWtBWyZAzqV2QFwGTJq0ack4sYtwBQMynekHMqqhqqpl2R7ruPCYPzofg6_046mhGDHotPuPep6OzOTS6moJPzU-GHopvQ-JD0AYvOYNIJ35LXgx4jvjvFS_Ljy-fHzW15_-3mbtPdl6ZmkEppesOslSB6irTXfVsJjcIyXfOe24EjDrbOixnWtE0D3ApJTdaNbSmtGbskH45998H_mjEmtXPR4DjqCf0cFW8la5hYjPJoNMHHGHBQ--B2OjwrCmrhp7bqH35q4bekMr9ce3UaMvc7tH8rT8CyYXM0YD714DCoaBxOBq0LaJKy3v3XmI8vupgxgzZ6_InPGLd-DlNmqaiKlQL1sDxy-SNwgApky_4AvtKdxQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>68935373</pqid></control><display><type>article</type><title>Posterior Juxtascleral Depot Administration of Anecortave Acetate</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Kaiser, Peter K., MD ; Goldberg, Morton F., MD ; Davis, Alberta A., PhD</creator><creatorcontrib>Kaiser, Peter K., MD ; Goldberg, Morton F., MD ; Davis, Alberta A., PhD ; The Anecortave Acetate Clinical Study Group ; Anecortave Acetate Clinical Study Group</creatorcontrib><description>Abstract Objective To develop a safe and effective transcleral delivery of anecortave acetate, a novel angiostatic cortisene, in therapeutic concentrations to the choroid and retina in the region of the macula in patients with age related macular degeneration. Methods In pre-clinical studies with rabbits and monkeys, several routes of delivery were studied including oral and other systemic routes as well as topical, subconjunctival, intravitreal injections and posterior juxtascleral administration. In addition, posterior juxtascleral depot administration using a specially designed blunt cannula was evaluated in humans. Results Oral and other systemic routes were not acceptable due to rapid systemic metabolism. Topical and subconjunctival administrations resulted in subtherapeutic concentrations in the macular region (<0.1 μm). Intravitreal injections resulted in adequate drug levels, but the visual axis was obscured due to the opaque nature of the drug, and this method carries risks of endophthalmitis and retinal detachment. Posterior juxtascleral depot administration in rabbits and monkeys resulted in adequate retinal and choroidal drug levels (≥0.1 μm) up to 6 months after administration. In clinical studies, this administration technique was found to be safe. Conclusions Posterior juxtascleral depot administration of anecortave acetate onto the scleral surface near the macula is a safe and effective method for delivering therapeutic concentrations of drug to the macular region of the choroid and retina for up to 6 months.</description><identifier>ISSN: 0039-6257</identifier><identifier>EISSN: 1879-3304</identifier><identifier>DOI: 10.1016/j.survophthal.2006.10.015</identifier><identifier>PMID: 17240258</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>AMD ; anecortave acetate ; Angiogenesis Inhibitors - administration & dosage ; Animals ; Catheterization ; Choroidal Neovascularization - drug therapy ; Drug Delivery Systems ; Drug Evaluation, Preclinical ; Humans ; Ophthalmology ; posterior juxtascleral depot (PJD) ; Pregnadienediols - administration & dosage ; Sclera</subject><ispartof>Survey of ophthalmology, 2007, Vol.52 (1), p.S62-S69</ispartof><rights>Elsevier Inc.</rights><rights>2007 Elsevier Inc.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c430t-9cbc3dd907b1e1bab827ae7d3a46b6df6eefd4172c3585506d791cdf6cd811433</citedby><cites>FETCH-LOGICAL-c430t-9cbc3dd907b1e1bab827ae7d3a46b6df6eefd4172c3585506d791cdf6cd811433</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0039625706002098$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,4010,27900,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/17240258$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kaiser, Peter K., MD</creatorcontrib><creatorcontrib>Goldberg, Morton F., MD</creatorcontrib><creatorcontrib>Davis, Alberta A., PhD</creatorcontrib><creatorcontrib>The Anecortave Acetate Clinical Study Group</creatorcontrib><creatorcontrib>Anecortave Acetate Clinical Study Group</creatorcontrib><title>Posterior Juxtascleral Depot Administration of Anecortave Acetate</title><title>Survey of ophthalmology</title><addtitle>Surv Ophthalmol</addtitle><description>Abstract Objective To develop a safe and effective transcleral delivery of anecortave acetate, a novel angiostatic cortisene, in therapeutic concentrations to the choroid and retina in the region of the macula in patients with age related macular degeneration. Methods In pre-clinical studies with rabbits and monkeys, several routes of delivery were studied including oral and other systemic routes as well as topical, subconjunctival, intravitreal injections and posterior juxtascleral administration. In addition, posterior juxtascleral depot administration using a specially designed blunt cannula was evaluated in humans. Results Oral and other systemic routes were not acceptable due to rapid systemic metabolism. Topical and subconjunctival administrations resulted in subtherapeutic concentrations in the macular region (<0.1 μm). Intravitreal injections resulted in adequate drug levels, but the visual axis was obscured due to the opaque nature of the drug, and this method carries risks of endophthalmitis and retinal detachment. Posterior juxtascleral depot administration in rabbits and monkeys resulted in adequate retinal and choroidal drug levels (≥0.1 μm) up to 6 months after administration. In clinical studies, this administration technique was found to be safe. Conclusions Posterior juxtascleral depot administration of anecortave acetate onto the scleral surface near the macula is a safe and effective method for delivering therapeutic concentrations of drug to the macular region of the choroid and retina for up to 6 months.</description><subject>AMD</subject><subject>anecortave acetate</subject><subject>Angiogenesis Inhibitors - administration & dosage</subject><subject>Animals</subject><subject>Catheterization</subject><subject>Choroidal Neovascularization - drug therapy</subject><subject>Drug Delivery Systems</subject><subject>Drug Evaluation, Preclinical</subject><subject>Humans</subject><subject>Ophthalmology</subject><subject>posterior juxtascleral depot (PJD)</subject><subject>Pregnadienediols - administration & dosage</subject><subject>Sclera</subject><issn>0039-6257</issn><issn>1879-3304</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2007</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkU1v1DAQhq0KRLeFv1CFC7dsx3FixxekaIG2qBJILWfLsSeql2y82M6K_nsc7UqgnjiN9M47X88Q8p7CmgLl19t1nMPB75_Skx7XFQDP-hpoc0ZWtBWyZAzqV2QFwGTJq0ack4sYtwBQMynekHMqqhqqpl2R7ruPCYPzofg6_046mhGDHotPuPep6OzOTS6moJPzU-GHopvQ-JD0AYvOYNIJ35LXgx4jvjvFS_Ljy-fHzW15_-3mbtPdl6ZmkEppesOslSB6irTXfVsJjcIyXfOe24EjDrbOixnWtE0D3ApJTdaNbSmtGbskH45998H_mjEmtXPR4DjqCf0cFW8la5hYjPJoNMHHGHBQ--B2OjwrCmrhp7bqH35q4bekMr9ce3UaMvc7tH8rT8CyYXM0YD714DCoaBxOBq0LaJKy3v3XmI8vupgxgzZ6_InPGLd-DlNmqaiKlQL1sDxy-SNwgApky_4AvtKdxQ</recordid><startdate>2007</startdate><enddate>2007</enddate><creator>Kaiser, Peter K., MD</creator><creator>Goldberg, Morton F., MD</creator><creator>Davis, Alberta A., PhD</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>2007</creationdate><title>Posterior Juxtascleral Depot Administration of Anecortave Acetate</title><author>Kaiser, Peter K., MD ; Goldberg, Morton F., MD ; Davis, Alberta A., PhD</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c430t-9cbc3dd907b1e1bab827ae7d3a46b6df6eefd4172c3585506d791cdf6cd811433</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2007</creationdate><topic>AMD</topic><topic>anecortave acetate</topic><topic>Angiogenesis Inhibitors - administration & dosage</topic><topic>Animals</topic><topic>Catheterization</topic><topic>Choroidal Neovascularization - drug therapy</topic><topic>Drug Delivery Systems</topic><topic>Drug Evaluation, Preclinical</topic><topic>Humans</topic><topic>Ophthalmology</topic><topic>posterior juxtascleral depot (PJD)</topic><topic>Pregnadienediols - administration & dosage</topic><topic>Sclera</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kaiser, Peter K., MD</creatorcontrib><creatorcontrib>Goldberg, Morton F., MD</creatorcontrib><creatorcontrib>Davis, Alberta A., PhD</creatorcontrib><creatorcontrib>The Anecortave Acetate Clinical Study Group</creatorcontrib><creatorcontrib>Anecortave Acetate Clinical Study Group</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Survey of ophthalmology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kaiser, Peter K., MD</au><au>Goldberg, Morton F., MD</au><au>Davis, Alberta A., PhD</au><aucorp>The Anecortave Acetate Clinical Study Group</aucorp><aucorp>Anecortave Acetate Clinical Study Group</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Posterior Juxtascleral Depot Administration of Anecortave Acetate</atitle><jtitle>Survey of ophthalmology</jtitle><addtitle>Surv Ophthalmol</addtitle><date>2007</date><risdate>2007</risdate><volume>52</volume><issue>1</issue><spage>S62</spage><epage>S69</epage><pages>S62-S69</pages><issn>0039-6257</issn><eissn>1879-3304</eissn><abstract>Abstract Objective To develop a safe and effective transcleral delivery of anecortave acetate, a novel angiostatic cortisene, in therapeutic concentrations to the choroid and retina in the region of the macula in patients with age related macular degeneration. Methods In pre-clinical studies with rabbits and monkeys, several routes of delivery were studied including oral and other systemic routes as well as topical, subconjunctival, intravitreal injections and posterior juxtascleral administration. In addition, posterior juxtascleral depot administration using a specially designed blunt cannula was evaluated in humans. Results Oral and other systemic routes were not acceptable due to rapid systemic metabolism. Topical and subconjunctival administrations resulted in subtherapeutic concentrations in the macular region (<0.1 μm). Intravitreal injections resulted in adequate drug levels, but the visual axis was obscured due to the opaque nature of the drug, and this method carries risks of endophthalmitis and retinal detachment. Posterior juxtascleral depot administration in rabbits and monkeys resulted in adequate retinal and choroidal drug levels (≥0.1 μm) up to 6 months after administration. In clinical studies, this administration technique was found to be safe. Conclusions Posterior juxtascleral depot administration of anecortave acetate onto the scleral surface near the macula is a safe and effective method for delivering therapeutic concentrations of drug to the macular region of the choroid and retina for up to 6 months.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>17240258</pmid><doi>10.1016/j.survophthal.2006.10.015</doi></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0039-6257 |
| ispartof | Survey of ophthalmology, 2007, Vol.52 (1), p.S62-S69 |
| issn | 0039-6257 1879-3304 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_68935373 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | AMD anecortave acetate Angiogenesis Inhibitors - administration & dosage Animals Catheterization Choroidal Neovascularization - drug therapy Drug Delivery Systems Drug Evaluation, Preclinical Humans Ophthalmology posterior juxtascleral depot (PJD) Pregnadienediols - administration & dosage Sclera |
| title | Posterior Juxtascleral Depot Administration of Anecortave Acetate |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-30T14%3A38%3A03IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Posterior%20Juxtascleral%20Depot%20Administration%20of%20Anecortave%20Acetate&rft.jtitle=Survey%20of%20ophthalmology&rft.au=Kaiser,%20Peter%20K.,%20MD&rft.aucorp=The%20Anecortave%20Acetate%20Clinical%20Study%20Group&rft.date=2007&rft.volume=52&rft.issue=1&rft.spage=S62&rft.epage=S69&rft.pages=S62-S69&rft.issn=0039-6257&rft.eissn=1879-3304&rft_id=info:doi/10.1016/j.survophthal.2006.10.015&rft_dat=%3Cproquest_cross%3E68935373%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=68935373&rft_id=info:pmid/17240258&rft_els_id=1_s2_0_S0039625706002098&rfr_iscdi=true |